Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hypertension, Portal 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 47lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 8apatinib 8Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × 6-acetylaminocaproic acid × Clear all
NCT06434753 2024-06-04

Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.

Hospital Universitari Vall d'Hebron Research Institute

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡